Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 70

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 70
---
 of an option, and shares subject to a stock-settled SAR that are not issued upon the net settlement of such SAR.

Awards granted under the 2025 Plan are subject to recoupment pursuant to the Company’s clawback policy, which is described in the Compensation Discussion & Analysis section of this Proxy Statement.

The 2025 Plan limits the number of awards that may be granted to Participants, and provides that no outside director shall receive options and SARs during a calendar year exceeding an aggregate grant date fair value of $500,000.

The exercise price of an option or SAR shall not be less than 100% of the fair market value of a share on the date of grant, and the maximum term of an option or SAR will not exceed ten years.

<div align='center'>51</div>

• The 2025 Plan has a term of ten years and, if approved by stockholders will expire May 30, 2035. The Size of Our Share Reserve Request Is Reasonable If stockholders approve the 2025 Plan, a total of 5,500,000 shares of stock will be available for issuance under the 2025 Plan, which will be subject to increase by shares that are subject to awards that were granted under the 2015 Plan, are still outstanding on the effective date of the 2025 Plan, and are later forfeited, expire, terminate, or are canceled without the delivery of all shares subject to the award, and subject to certain equitable substitutions or adjustments determined by the Administrator for certain changes in capitalization set forth under the 2025 Plan. Similar recycling will also apply to awards granted under the 2025 Plan. • The proposed share request is projected to enable equity grants for at least two years. o After a review of our historical practices and in the context of our current and expected future growth, management has determined that the proposed initial reserve of 5,500,000 shares, which represents the equivalent of 11.1% of our shares of common stock outstanding as of December 31, 2024, is appropriate to cover our anticipated requirements to attract and retain top talent until at least the 2027 annual meeting of stockholders. The proposed share pool is approximately two times the three-year annual average of our gross equity burn rate. o We are on the cusp of realizing commercialization of our late-stage clinical product candidates. The proposed share pool request is made in the context of our need to retain and attract employees primarily in support of not only our